[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,034,822
  • Shares Outstanding, K 62,377
  • Annual Sales, $ 814,760 K
  • Annual Income, $ -258,000 K
  • EBIT $ -154 M
  • EBITDA $ -134 M
  • 60-Month Beta 0.49
  • Price/Sales 17.69
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 42.41% (-1.47%)
  • Historical Volatility 36.05%
  • IV Percentile 15%
  • IV Rank 14.58%
  • IV High 70.31% on 08/01/25
  • IV Low 37.64% on 06/16/25
  • Expected Move (DTE 21) 15.94 (7.13%)
  • Put/Call Vol Ratio 0.65
  • Today's Volume 466
  • Volume Avg (30-Day) 536
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 9,432
  • Open Int (30-Day) 16,337
  • Expected Range 207.46 to 239.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.21
  • Number of Estimates 8
  • High Estimate $0.81
  • Low Estimate $-0.42
  • Prior Year $-1.66
  • Growth Rate Est. (year over year) +112.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
215.02 +4.98%
on 03/30/26
250.74 -9.97%
on 04/13/26
+10.19 (+4.73%)
since 03/24/26
3-Month
211.00 +6.98%
on 02/12/26
250.74 -9.97%
on 04/13/26
-9.66 (-4.10%)
since 01/23/26
52-Week
150.89 +49.60%
on 05/15/25
250.74 -9.97%
on 04/13/26
+65.28 (+40.69%)
since 04/24/25

Most Recent Stories

More News
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible...

ASND : 228.28 (+1.46%)
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq),...

ASND : 228.28 (+1.46%)
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

 - Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs)  - ADS holders will receive one ordinary share listed on Nasdaq...

ASND : 228.28 (+1.46%)
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia

- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community - Enhanced improvements in spinal...

ASND : 228.28 (+1.46%)
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially...

ASND : 228.28 (+1.46%)
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children  - TransCon hGH showed a safety and tolerability...

ASND : 228.28 (+1.46%)
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with...

ASND : 228.28 (+1.46%)
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference

COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual...

ASND : 228.28 (+1.46%)
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing interval Commercial availability expected during early part of Q2 2026 Rare...

ASND : 228.28 (+1.46%)
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 million Q4 2025 operating profit of €10 million and cash flow from operating activities of €73 million TransCon...

ASND : 228.28 (+1.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 236.90
2nd Resistance Point 234.25
1st Resistance Point 229.62
Last Price 228.28
1st Support Level 222.35
2nd Support Level 219.70
3rd Support Level 215.07

See More

52-Week High 250.74
Last Price 228.28
Fibonacci 61.8% 212.60
Fibonacci 50% 200.82
Fibonacci 38.2% 189.03
52-Week Low 150.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.